Welcome to the Market Access Podcast, your expert briefing on the latest in Market Access and Health Economics in the Bio-Pharmaceutical Industries.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress
20:34
20:34
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
20:34
We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fat…
…
continue reading
In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing. Experts on callUlrich Neumann, Sr. Director, US Access ulrich.neumann@certara.comAdditional notes: - We referenced the Implications of Pricing on Innovation which is thoroughly discussed …
…
continue reading
Listen in for this stakeholder panel on strategic collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients. Experts on callShontelle Dodson, SVP, AstellasMatt Portch, VP Sunovion,Gergana Zlateva, VP Pfizer,Terrill Jordan, CEO of the RCCA provider networkUlrich Neumann, Sr. Director, Head US Access, Certar…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
(1): Outcomes Based Agreements: Deal or No Deal
1:07:38
1:07:38
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
1:07:38
In our first episode, we're shining a light on the next frontier for outcomes-based agreements (OBA). If we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting? Experts Roman Casciano, GM, Analytica Laser & SVP, Market Access, HEOR and Real-world Evidence, CertaraLee Stern, VP, Business Deve…
…
continue reading